{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T02:27:13Z","timestamp":1778034433484,"version":"3.51.4"},"reference-count":24,"publisher":"American Diabetes Association","issue":"8","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,8,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Insulin degludec\/insulin aspart (IDegAsp) is the first combination of a basal insulin with an ultralong duration of action, and a rapid-acting insulin in a single injection. This trial compared IDegAsp with biphasic insulin aspart 30 (BIAsp 30) in adults with type 2 diabetes inadequately controlled with once- or twice-daily (OD or BID) pre- or self-mixed insulin with or without oral antidiabetic drugs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>In this 26-week, randomized, open-label, multinational, treat-to-target trial, participants (mean age 58.7 years, duration of diabetes 13 years, BMI 29.3 kg\/m2, and HbA1c 8.4% [68 mmol\/mol]) were exposed (1:1) to BID injections of IDegAsp (n = 224) or BIAsp 30 (n = 222), administered with breakfast and the main evening meal and dose titrated to a self-measured premeal plasma glucose (PG) target of 4.0\u20135.0 mmol\/L.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>After 26 weeks, mean HbA1c was 7.1% (54 mmol\/mol) for both groups, with IDegAsp achieving the prespecified noninferiority margin for mean change in HbA1c (estimated treatment difference [ETD] \u20130.03% points [95% CI \u20130.18 to 0.13]). Treatment with IDegAsp was superior in lowering fasting PG (ETD \u20131.14 mmol\/L [95% CI \u20131.53 to \u20130.76], P &amp;lt; 0.001) and had a significantly lower final mean daily insulin dose (estimated rate ratio 0.89 [95% CI 0.83\u20130.96], P = 0.002). Fewer confirmed, nocturnal confirmed, and severe hypoglycemia episodes were reported for IDegAsp compared with BIAsp 30.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>IDegAsp BID effectively improves HbA1c and fasting PG levels with fewer hypoglycemia episodes versus BIAsp 30 in patients with uncontrolled type 2 diabetes previously treated with once- or twice-daily pre- or self-mixed insulin.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc13-2908","type":"journal-article","created":{"date-parts":[[2014,5,9]],"date-time":"2014-05-09T09:23:45Z","timestamp":1399627425000},"page":"2084-2090","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":98,"title":["Comparison of Insulin Degludec\/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial"],"prefix":"10.2337","volume":"37","author":[{"given":"Gregory R.","family":"Fulcher","sequence":"first","affiliation":[{"name":"University of Sydney, Royal North Shore Hospital, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens Sandahl","family":"Christiansen","sequence":"additional","affiliation":[{"name":"Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganapathi","family":"Bantwal","sequence":"additional","affiliation":[{"name":"St. Johns Medical College Hospital, Bangalore, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslawa","family":"Polaszewska-Muszynska","sequence":"additional","affiliation":[{"name":"Bydgoszcz Diabetes and Endocrinology Center, Bydgoszcz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henriette","family":"Mersebach","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas H.","family":"Andersen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo K.","family":"Niskanen","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Eastern Finland, Helsingfors, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2014,7,12]]},"reference":[{"key":"2022031219465534900_B1","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031219465534900_B2","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-year efficacy of complex insulin regimens in type 2 diabetes","volume":"361","author":"Holman","year":"2009","journal-title":"N Engl J Med"},{"key":"2022031219465534900_B3"},{"key":"2022031219465534900_B4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pec.2007.05.003","article-title":"A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education","volume":"68","author":"Wild","year":"2007","journal-title":"Patient Educ Couns"},{"key":"2022031219465534900_B5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031219465534900_B6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1525-1497.2005.0117.x","article-title":"Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens","volume":"20","author":"Vijan","year":"2005","journal-title":"J Gen Intern Med"},{"key":"2022031219465534900_B7","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1463-1326.2006.00654.x","article-title":"Premixed insulin treatment for type 2 diabetes: analogue or human?","volume":"9","author":"Garber","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"2022031219465534900_B8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.2165\/11635490-000000000-00000","article-title":"Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings","volume":"72","author":"Liebl","year":"2012","journal-title":"Drugs"},{"key":"2022031219465534900_B9","first-page":"186","article-title":"Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management","volume":"29","author":"Leiter","year":"2005","journal-title":"Can J Diabetes"},{"key":"2022031219465534900_B10","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","article-title":"Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study","volume":"29","author":"Peyrot","year":"2012","journal-title":"Diabet Med"},{"key":"2022031219465534900_B11","article-title":"Ultra-long acting insulin degludec can be combined with rapid-acting insulin aspart in a soluble co-formulation","volume":"16","author":"Jonassen","year":"2010","journal-title":"J Pept Sci"},{"key":"2022031219465534900_B12","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1177\/193229681000400320","article-title":"Assessment of the mixing efficiency of neutral protamine Hagedorn cartridges","volume":"4","author":"Kaiser","year":"2010","journal-title":"J Diabetes Sci Tech"},{"key":"2022031219465534900_B13"},{"key":"2022031219465534900_B14"},{"key":"2022031219465534900_B15","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1463-1326.2012.01638.x","article-title":"Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes","volume":"14","author":"Heise","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2022031219465534900_B16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/dom.12032","article-title":"Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials","volume":"15","author":"Ratner","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2022031219465534900_B17","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2337\/dc12-1668","article-title":"The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes","volume":"36","author":"Meneghini","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031219465534900_B18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1530\/EJE-12-0293","article-title":"Comparison of a soluble co-formulation of insulin degludec\/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial","volume":"167","author":"Niskanen","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"2022031219465534900_B19","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Guideline for Good Clinical Practice guidelines. Available from http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6_R1\/Step4\/E6_R1__Guideline.pdf. Accessed 11 April 2014"},{"key":"2022031219465534900_B20"},{"key":"2022031219465534900_B21","article-title":"Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec","volume":"54","author":"Kurtzhals","year":"2011","journal-title":"Diabetologia"},{"key":"2022031219465534900_B22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1530\/EJE-11-0022","article-title":"Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues","volume":"166","author":"Vaag","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"2022031219465534900_B23"},{"key":"2022031219465534900_B24"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/8\/2084\/622248\/2084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/37\/8\/2084\/622248\/2084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T21:29:58Z","timestamp":1647120598000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/37\/8\/2084\/30093\/Comparison-of-Insulin-Degludec-Insulin-Aspart-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,12]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,7,12]]},"published-print":{"date-parts":[[2014,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc13-2908","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,12]]}}}